Literature DB >> 2029808

Pharmacodynamic modelling. Application to new drug development.

P D Kroboth1, V D Schmith, R B Smith.   

Abstract

Mesh：

Year:  1991        PMID： 2029808     DOI： 10.2165/00003088-199120020-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  22 in total

1.  Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects.

Authors:  P D Kroboth; R B Smith; R J Erb
Journal:  Clin Pharmacol Ther       Date:  1988-03       Impact factor: 6.875

2.  Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited.

Authors:  D R Stanski; P O Maitre
Journal:  Anesthesiology       Date:  1990-03       Impact factor: 7.892

3.  Semiparametric approach to pharmacokinetic-pharmacodynamic data.

Authors:  D Verotta; S L Beal; L B Sheiner
Journal:  Am J Physiol       Date:  1989-04

4.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

5.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

Authors:  J D Unadkat; F Bartha; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

6.  Reduction of digoxin effect during the digoxin-quinidine interaction.

Authors:  G Das; C E Barr; J Carlson
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

7.  Development of a model for integrated pharmacokinetic and pharmacodynamic studies of intravenous anaesthetic agents: applications to minaxolone.

Authors:  L E Mather; L T Seow; J G Roberts; G K Gourlay; M J Cousins
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man.

Authors:  P Chennavasin; R Seiwell; D C Brater
Journal:  J Pharmacol Exp Ther       Date:  1980-10       Impact factor: 4.030

9.  Pharmacodynamics of triazolam after intravenous administration.

Authors:  R B Smith; P D Kroboth; P D Varner
Journal:  J Clin Pharmacol       Date:  1987-12       Impact factor: 3.126

10.  Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers.

Authors:  R L Lalonde; R J Straka; J A Pieper; M B Bottorff; D M Mirvis
Journal:  J Pharmacokinet Biopharm       Date:  1987-12
View more
  12 in total

1.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 2.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

3.  Estimation of Cmax and Tmax in populations after single and multiple drug administrations.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-10       Impact factor: 2.745

Review 4.  Medication screening for smoking cessation: a proposal for new methodologies.

Authors:  Kenneth A Perkins; Maxine Stitzer; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-09-15       Impact factor: 4.530

Review 5.  Methodological issues in pharmacokinetic-pharmacodynamic modelling.

Authors:  E Bellissant; V Sébille; G Paintaud
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 6.  The use of population pharmacokinetics in drug development.

Authors:  S Vozeh; J L Steimer; M Rowland; P Morselli; F Mentre; L P Balant; L Aarons
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 7.  Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma.

Authors:  R P Koopmans; R E Jonkers; M C Braat; C J van Boxtel
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

Review 8.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 9.  An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.

Authors:  Kenneth A Perkins; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2013-12-03       Impact factor: 4.530

10.  Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers.

Authors:  E Bellissant; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.